At the pulse of heart disease

We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.

News

Cardior Pharma Trend Award 2022
Cardior wins Pharma Trend Award „Das Innovativste Produkt” Sprunginnovation

Cardior’s lead candidate CDR132L has been recognized as the most innovative product in the category “Sprunginnovation” at the Pharma Trend Awards 2022. Listen to our CEO Dr. Claudia Ulrich and CSO Prof. Thomas Thum as they explain the distinct features of CDR132L, Cardior’s approach to cardiac diseases and our evolution as a company.

Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study

Hanover, Germany, September 8, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the CE marking of its PCR kit which measures circulating microRNA-132 (miR-132) levels in the blood of patients receiving the company’s lead candidate CDR132L, an oligonucleotide-based miR-132 inhibitor.

Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA-Based Lead Candidate CDR132L in Heart Failure Patients Post-Myocardial Infarction

Hanover, Germany, July 20, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT).